These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 8446933)

  • 21. Factor VIII inhibitors in previously treated haemophilia A patients with a double virus-inactivated plasma derived factor VIII concentrate.
    Peerlinck K; Arnout J; Di Giambattista M; Gilles JG; Laub R; Jacquemin M; Saint-Remy JM; Vermylen J
    Thromb Haemost; 1997 Jan; 77(1):80-6. PubMed ID: 9031454
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The need for previously untreated patient population studies in understanding the development of factor VIII inhibitors.
    Gomperts ED
    Haemophilia; 2006 Nov; 12(6):573-8. PubMed ID: 17083506
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibitor antibody development and T cell response to human factor VIII in murine hemophilia A.
    Qian J; Borovok M; Bi L; Kazazian HH; Hoyer LW
    Thromb Haemost; 1999 Feb; 81(2):240-4. PubMed ID: 10063999
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clearance of cryoprecipitated factor VIII in canine hemophilia A.
    Aufderheide WM; Skinner SF; Kaneko JJ
    Am J Vet Res; 1975 Apr; 36(4 Pt.1):367-70. PubMed ID: 1124873
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Von Willebrand factor modulates factor VIII immunogenicity: comparative study of different factor VIII concentrates in a haemophilia A mouse model.
    Behrmann M; Pasi J; Saint-Remy JM; Kotitschke R; Kloft M
    Thromb Haemost; 2002 Aug; 88(2):221-9. PubMed ID: 12195693
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hemophilia. Strategies for the treatment of inhibitor patients.
    Ingerslev J
    Haematologica; 2000 Oct; 85(10 Suppl):15-20. PubMed ID: 11187863
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A detailed comparison of the performance of the standard versus the Nijmegen modification of the Bethesda assay in detecting factor VIII:C inhibitors in the haemophilia A population of Canada. Association of Hemophilia Centre Directors of Canada. Factor VIII/IX Subcommittee of Scientific and Standardization Committee of International Society on Thrombosis and Haemostasis.
    Giles AR; Verbruggen B; Rivard GE; Teitel J; Walker I
    Thromb Haemost; 1998 Apr; 79(4):872-5. PubMed ID: 9569207
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A higher than expected incidence of factor VIII inhibitors in multitransfused haemophilia A patients treated with an intermediate purity pasteurized factor VIII concentrate.
    Peerlinck K; Arnout J; Gilles JG; Saint-Remy JM; Vermylen J
    Thromb Haemost; 1993 Feb; 69(2):115-8. PubMed ID: 8456422
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibitors in young boys with haemophilia.
    Lusher JM
    Baillieres Best Pract Res Clin Haematol; 2000 Sep; 13(3):457-68. PubMed ID: 11030045
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Haemophilia A: mutation type determines risk of inhibitor formation.
    Schwaab R; Brackmann HH; Meyer C; Seehafer J; Kirchgesser M; Haack A; Olek K; Tuddenham EG; Oldenburg J
    Thromb Haemost; 1995 Dec; 74(6):1402-6. PubMed ID: 8772209
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Macrohaematuria post-partum: an unusual case of acquired haemophilia after pregnancy].
    Prencipe MA; D'Errico M; Di Giorgio G; Gatta G; Gesuete A; Nobile M; Stallone C
    G Ital Nefrol; 2002; 19(2):204-8. PubMed ID: 12195420
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The suppression of factor VIII antibodies in haemophilia.
    Dormandy KM; Sultan Y
    Pathol Biol (Paris); 1975 Dec; 23 suppl():17-23. PubMed ID: 772555
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Determination of coagulation factor VIII inhibitors].
    Lutze G; Schlote A; Mittler U
    Z Gesamte Inn Med; 1980 Apr; 35(8):330-6. PubMed ID: 6776700
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Factor VIII-bypassing activity of bovine tissue factor using the canine hemophilic model.
    O'Brien DP; Giles AR; Tate KM; Vehar GA
    J Clin Invest; 1988 Jul; 82(1):206-11. PubMed ID: 3134399
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genetic risk factors for inhibitors to factors VIII and IX.
    Oldenburg J; Pavlova A
    Haemophilia; 2006 Dec; 12 Suppl 6():15-22. PubMed ID: 17123389
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hemophilia factor VIII therapy. Immunological tolerance. A clinical perspective.
    White GC; Greenwood R; Escobar M; Frelinger JA
    Haematologica; 2000 Oct; 85(10 Suppl):113-6. PubMed ID: 11187862
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relationship between factor VIII mutation type and inhibitor development in a cohort of previously untreated patients treated with recombinant factor VIII (Recombinate). Recombinate PUP Study Group.
    Goodeve AC; Williams I; Bray GL; Peake IR
    Thromb Haemost; 2000 Jun; 83(6):844-8. PubMed ID: 10896236
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel therapies for immune tolerance in haemophilia A.
    Collins PW
    Haemophilia; 2006 Dec; 12 Suppl 6():94-100; discussion 100-1. PubMed ID: 17123401
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Comparison of anti-human and anti-porcine factor VIII antibody titers in patients with hemophilia].
    Windyga J; Rzymkiewicz L; Lopaciuk S
    Acta Haematol Pol; 1996; 27(1):27-31. PubMed ID: 8629440
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Spontaneous disappearance of high titre factor VIII inhibitor 15 years after unsuccessful ITI.
    Thom K; Male C; Falger J; Pabinger I
    Hamostaseologie; 2009 May; 29(2):149-50. PubMed ID: 19404512
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.